News

In this new role, Mr Ross will oversee Axial Biotech’s global efforts to identify, evaluate, and pursue new diagnostic opportunities and will help to coordinate the company’s long-term

The FDA has stated that there are no outstanding safety concerns with the device and granted Phase III initiation. Arthrosurface has been evaluating the safety and efficacy of

Ed Gallo, executive vice president of Concuity, said: “ClearContracts is a proven system that optimizes the revenue management cycle. We’re delighted to have Valley Baptist select ClearContracts for

Pillar SA is said to be the latest addition to Orthofix’s line of Pillar Peek spacer systems. The new spinal device is designed to be used in most

Cryoablation of cancer in the prostate will employ technology provided by Endocare, Irvine, California. Virgin dendritic cells (VDC2008) consist of each patient’s own immature dendritic cells obtained from

Most recently, Mr Beery has served as US Airways’s senior vice president and chief information officer, responsible for all IT business and operational systems and applications, process improvements,

Sunesis and SARcode have previously entered into a license agreement providing SARcode with an exclusive license to Sunesis’s LFA-1 technology to develop LFA-1 inhibitors. As part of the

This is a Phase II multi-center, parallel group, randomized study of palIfosfamide plus doxorubicin versus doxorubiCin in subjects with unresectable or metastatic soft-tissue sarcoma. Approximately 100 evaluable subjects

These new positions were created to support the company’s efforts to identify and pursue important growth opportunities for HP Acthar Gel. Mr O’Neill was senior director for biopharmaceuticals